Explore
Search ClinicalTrials.gov
Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.
Results for “AstraZeneca”
Sponsor: AstraZeneca
Type 2 Diabetes Mellitus
United States, Argentina, China, Denmark, Greece +8 more
- China CRSwNP Registry StudyNot Yet Recruiting
Sponsor: Beijing Tongren Hospital
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
China
- Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate CancerRecruiting
Sponsor: AstraZeneca
Metastatic Prostate Cancer
United States, Brazil, China, France, Italy +5 more
Sponsor: AstraZeneca
Lupus Erythematosus, Systemic
Germany
Sponsor: AstraZeneca
COVID-19 · SARS-CoV-2 Infection
United States
- A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)Active Not Recruiting
Sponsor: AstraZeneca
Carcinoma, Non-Small-Cell Lung · Triple Negative Breast Cancer
China
- Volrustomig Priming Regimens Exploratory Phase II Platform StudyActive Not Recruiting
Sponsor: AstraZeneca
Non-small Cell Lung Cancer
United States, China, France, Georgia, Greece +9 more
- Real-world Study Assessing Efficacy of TezepeLumaB in Patients With Severe Asthma Regardless of Phenotype in RussiaActive Not Recruiting
Sponsor: AstraZeneca
Severe Asthma
Russia
- Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)Active Not Recruiting
Sponsor: AstraZeneca
Metastatic Castration-resistant Prostate Cancer
China
Sponsor: University of Pennsylvania
Eosinophilic Granulomatosis With Polyangiitis · Churg-Strauss Syndrome
United States, Canada, Germany, Italy, United Kingdom
- Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR)Recruiting
Sponsor: AstraZeneca
Severe Asthma
Russia
Sponsor: AstraZeneca
Viral Lung Infection and Acute Respiratory Failure
United States, Argentina, Australia, Belgium, Brazil +34 more
Sponsor: AstraZeneca
B-cell Non-Hodgkin Lymphoma
United States, Australia, China, Italy, Japan +3 more
- A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLCActive Not Recruiting
Sponsor: AstraZeneca
Non-Small Cell Lung Cancer
United States, Belgium, Brazil, Canada, Chile +23 more
Sponsor: AstraZeneca
Severe Eosinophilic Asthma
Italy
- A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy ParticipantsActive Not Recruiting
Sponsor: AstraZeneca
Healthy Participants
United States
Sponsor: AstraZeneca
Asthma, Bronchial
Germany
- Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.Recruiting
Sponsor: AstraZeneca
Lupus Erythematosus, Systemic
Italy
- Ondexxya for Intravenous Injection 200mg Drug Use Result Investigation (All Case Investigation)Recruiting
Sponsor: AstraZeneca
Life Threatening Bleeding · Factor Xa Inhibitor
Japan
- Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)Active Not Recruiting
Sponsor: AstraZeneca
Gastric Cancer
United States, Brazil, Canada, China, Germany +9 more
- A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast CancerRecruiting
Sponsor: AstraZeneca
Breast Cancer
United States, China, France, Italy, South Korea +1 more
- Tezepelumab CRSwNP Real World Study (CREW Study)Not Yet Recruiting
Sponsor: AstraZeneca
Chronic Rhinosinusitis With Nasal Polyps
- Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an IleostomyActive Not Recruiting
Sponsor: AstraZeneca
Crohn's Disease
Belgium, Italy, Netherlands, Poland, Sweden +2 more
Sponsor: AstraZeneca
Obesity · Overweight
China, Hong Kong, Malaysia, Philippines, Thailand
Sponsor: AstraZeneca
Advanced Solid Tumors That Are MTAP Deficient
United States, Australia, China, France, Japan +3 more